Aim: Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Pa... Plain language summary Reduced risk of cancer spreading in Spanish patients with nonmetastatic castration-resistant prostate cancer treated with darolutamide in the global ARAMIS study Darolutamide... Tweetable abstract For Spanish patients with nmCRPC in ARAMIS, darolutamide increased metastasis-free survival and PSA response versus placebo. Adverse event incidence was similar in both arms. Out... Graphical abstract
High-intensity focused ultrasound (HIFU) competes with radiofrequency and cryotherapy for the treatment of small renal masses as a third option among ablative approaches. As an emerging technique, its possible percutaneous or laparoscopic application, low discomfort to the patient and the absence of complications make this technology attractive for the management of small renal masses. This manuscript will focus on the principles, basic research and clinical applications of HIFU in small renal masses, reviewing the present literature. Therapeutic results are controversial and from an clinical view, HIFU must be considered a technique under investigation at present time. Further research is needed to settle its real indications in the management of small renal masses; maybe technical improvements will certainly facilitate its use in the management of small renal masses in the near future.